SEOUL, Feb 1 (Reuters) - South Korea's Celltrion Inc shares fell almost 3 percent on Thursday, after the biopharma company said it had received a warning letter from the U.S. Food and Drug Administration (FDA).
The letter asked Celltrion to turn in supplemental documents about changes the FDA had asked for regarding its pharmaceutical production, Celltrion said in a statement on its website.
The supplemental documents are part of an ordinary process for the pharmaceutical industry and will be turned in 15 business days as required, a Celltrion spokeswoman said.
(Reporting by Joyce Lee; Editing by Himani Sarkar)
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.